Hematological Malignancies

Conclusions • Risk of hematological SMNs has decreased over time • Risk solid SMNs does not appear to decrease in patients treated before 2000, potentially due to changes in chemotherapy regimens and more breast cancer screening. • Awareness of increased SMN risk remains crucial for HL survivors.

Schaapveld et al , submitted